References
- Ferreri AJ, Blay JY, Reni M, . Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21:266–272.
- Abrey LE, Ben-Porat L, Panageas KS, . Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006;24:5711–5715.
- Ferreri AJ, Reni M, Pasini F, . A multicenter study of treatment of primary CNS lymphoma. Neurology 2002;58:1513–1520.
- Ferreri AJ, Reni M, Foppoli M, . High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009;374:1512–1520.
- O'Brien P, Seymour JF. Progress in primary CNS lymphoma. Lancet 2009;374:1477–1478.
- O'Brien P, Roos D, Pratt G, . Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000;18:519–526.
- Corry J, Smith JG, Wirth A, . Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 1998;41:615–620.
- Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000;18:3144–3150.
- DeAngelis LM. Radiotherapy: has the role of WBRT in primary CNS lymphoma been settled? Nat Rev Clin Oncol 2011;8:196–198.
- Thiel E, Korfel A, Martus P, . High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010;11:1036–1047.
- Ferreri AJ, DeAngelis L, Illerhaus G, . Whole-brain radiotherapy in primary CNS lymphoma. Lancet Oncol 2011;12:118–119; author reply 119–120.
- Cabanillas F. How important is whole brain radiotherapy for treatment of primary CNS lymphoma? Lancet Oncol 2010;11:1011–1012.
- Bessell EM, López-Guillermo A, Villá S, . Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002;20:231–236.
- Shah GD, Yahalom J, Correa DD, . Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25:4730–4735.
- Correa DD, Rocco-Donovan M, DeAngelis LM, . Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol 2009;91:315–321.
- Ferreri AJ. How I treat primary CNS lymphoma. Blood 2011 May 25. [Epub ahead of print]
- Motomura K, Natsume A, Fujii M, . Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. Leuk Lymphoma 2011;52:2069–2075.
- Ferreri AJ, Dell'Oro S, Capello D, . Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol 2004;126:657–664.
- Koto M, Cho H, Riesterer O, . Human lymphoma cells develop resistance to radiation in the presence of astrocytes in vitro. Anticancer Res 2011;31:33–38.
- Montesinos-Rongen M, Siebert R, Deckert M. Primary lymphoma of the central nervous system: just DLBCL or not? Blood 2009;113:7–10.
- Abrey LE, Batchelor TT, Ferreri AJ, . Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034–5043.
- Abrey LE, Panageas KS. Identifying and addressing barriers to the delivery of optimal therapy for primary central nervous system lymphoma in the broader community. Leuk Lymphoma 2006;47:2449–2452.